Early cancer drug trial halted after safety testing
NCT ID NCT05194072
Summary
This early-stage study aimed to test the safety and find the right dose of a new drug called Felmetatug Vedotin for people with advanced solid tumors. It was for adults with cancers like ovarian, breast, lung, and others that had spread or could not be removed by surgery. The trial was terminated, meaning it was stopped early, and its main goal was to understand the drug's side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Celebration Infusion Center
Celebration, Florida, 34747, United States
-
AdventHealth Medical Group Oncology Research at Celebration
Celebration, Florida, 34747, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46227, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46250, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46256, United States
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Hamato-Onkologische Phase 1 Unit der Charite/Charite Research Organisation
Berlin, 12200, Germany
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Northwestern Medical Group
Chicago, Illinois, 60611, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Presbyterian/St Lukes Medical Center
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Madrid-Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas, 77030, United States
-
UCHealth Sue Anschutz-Rodgers Eye Center
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.